Manufacturers' early commitment to emerging Asian markets key to long-term success -- HIMA's Zavada.
This article was originally published in The Gray Sheet
Executive Summary
DEVICE FIRMS' COMMITMENT TO EMERGING ASIAN MARKETS during early years of economic fluctuation should pay off in the long-term as the markets enter periods of sustained growth, Terri Zavada, the Health Industry Manufacturers Association's director for global strategy and analysis, said during a June 27 briefing in Washington, D.C. Companies "definitely have to be there in the formative stages in order to be a really strong player when the market" begins to stabilize, Zavada said. HIMA held the briefing to announce release of its 1996 "Emerging Markets Report."
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.